InterCure Ltd. Share Price TEL AVIV STOCK EXCHANGE

INCR

IL0011063760

Healthcare Facilities & Services

News in other languages: InterCure Ltd.

02/01/20

Tilray, Inc. : première exportation de cannabis vers Israël

More news

Managers and Directors: InterCure Ltd.

Manager	Title	Age	Since
Alexander Rabinovitch CEO	Chief Executive Officer	55	23/12/2019
Amos Cohen DFI	Director of Finance/CFO	47	29/02/2020
Itai Kabiljo LAW	General Counsel	-	31/03/2022

Director	Title	Age	Since
Alexander Rabinovitch CHM	Chairman	55	12/02/2025
Alon Shmuel Granot BRD	Director/Board Member	65	31/10/2020
David Salton BRD	Director/Board Member	66	13/12/2014

More insiders

InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

Employees

Sector

Healthcare Facilities & Services

More about the company

Market Cap	173M 519M 152M 140M 131M 246M 16.34B 251M 1.68B 651M 8.07B 650M 636M 28B	P/E 2024	-4.01x	P/E 2025	-4.87x
Enterprise Value	310M 928M 271M 250M 234M 439M 29.2B 448M 3.01B 1.16B 14.43B 1.16B 1.14B 50.04B	EV / Sales 2024	1.69x	EV / Sales 2025	1.16x
Free-Float	75.95%	Yield 2024 *	-	Yield 2025	-

06-22	InterCure Ltd. announced that it expects to receive ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors.	CI
06-15	InterCure Starts Review of US Medical Cannabis Opportunities; Completes Initial Closing of Botanico Acquisition	MT
06-14	InterCure Ltd. acquired 50% stake of Botanico Ltd.	CI
06-14	InterCure Ltd. completed the acquisition of 50% stake in Botanico Ltd.	CI
04-30	InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-03	InterCure Receives Noncompliance Notice From Nasdaq	MT
03-03	InterCure receives Nasdaq notification regarding minimum bid requirement	RE
02-19	InterCure announces preliminary estimated 2025 revenue of NIS 265 million, positive adjusted EBITDA and cash of NIS 43 million	RE
12-18	InterCure Ltd on Dec 15, became aware that Bazelet Group of Companies has initiated Restructuring proceedings before the Israeli district court	RE
11-03	Cannasoul Analytics Ltd. announced that it expects to receive funding from InterCure Ltd.	CI
11-03	InterCure Ltd. Enters into A Collaboration Agreement with Cannasoul R&D Ltd	CI
08/10/25	InterCure Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
08/10/25	Intercure reports first half 2025 results with NIS 130 million in revenue and positive operating cash flow	RE

06-22	InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds	AQ
06-15	InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition	AQ
04-30	InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow	AQ
03-03	InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement	AQ
02-19	InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTERCURE LTD.	+0.22%	-0.51%	-	-	57.73M
CORDYCEPS SUNSHINE BIOTECH HOLDINGS CO., LTD.	+72.76%	-.--%	-39.25%	-	578M
VILLAGE FARMS INTERNATIONAL, INC.	+2.72%	-1.05%	+76.64%	+220.28%	216M
ORGANIGRAM GLOBAL INC.	+7.35%	+5.80%	-20.65%	-27.00%	145M
CANNARA BIOTECH INC.	+5.00%	+1.82%	+22.63%	+97.65%	117M
ASCEND WELLNESS HOLDINGS, INC.	+11.11%	-3.85%	+61.29%	-20.63%	101M
JUSHI HOLDINGS INC.	+0.92%	+1.04%	+67.24%	-0.02%	96.85M
Average	+14.30%	+0.63%	+27.98%	+54.06%	209M
Weighted average by Cap.	+34.69%	+0.43%	+4.99%	+78.38%

	2024	2025
Net sales	239M 716M 209M 193M 181M 339M 22.53B 346M 2.32B 898M 11.14B 897M 877M 38.61B	270M 811M 237M 218M 204M 383M 25.49B 391M 2.62B 1.02B 12.6B 1.01B 992M 43.68B
Net income	-67.8M -203M -59.44M -54.79M -51.3M -96.19M -6.4B -98.19M -659M -255M -3.16B -255M -249M -10.96B	-35.71M -107M -31.31M -28.86M -27.02M -50.67M -3.37B -51.72M -347M -134M -1.66B -134M -131M -5.77B
Net Debt	133M 398M 116M 107M 100M 188M 12.52B 192M 1.29B 499M 6.19B 498M 488M 21.46B	136M 409M 120M 110M 103M 193M 12.86B 197M 1.32B 512M 6.36B 512M 501M 22.04B

InterCure Ltd. Share Price TEL AVIV STOCK EXCHANGE

Stocks

INCR

IL0011063760

Healthcare Facilities & Services

Valuation: InterCure Ltd.

Latest news : InterCure Ltd.

Press Releases: InterCure Ltd.

News in other languages: InterCure Ltd.

Quotes and Performance

Managers and Directors: InterCure Ltd.

Medical Farming

Financials

Company Profile